MedDRA - Acute myocardial infarction. Code: 10000891 I21
Conditions
Interventions
Group 1: Observational group Thienopyridine pre-treated patients.
The following data will be recorded: Data related to demography, medical history, medical condition, the medication the patient receiv
Sponsors
Daiichi Sankyo Europe GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • At least 18 years of age / • Started antiplatelet therapy with a thienopyridine agent upstream based on an initial STEMI diagnosis before arrival at the cathlab hospital according to the authorization of the drug or standard of care. / • Transported to the cathlab (study centre) hospital by ambulance with the intention to perform primary angioplasty (patients can be picked-up from home or from a referring hospital) / • Written informed consent for participation in the NIS / • No current or planned enrolment in a clinical study. Exception: Patients with current or planned enrolment in a clinical study can be included if all of the following conditions are met: a) The patient’s treatment with thienopyridine antiplatelet drugs is not determined by the clinical study protocol but is performed according to the terms of authorization of the drug or standard of care - b) The patient’s actual treatment with antiplatelet drugs and anticoagulants is fully known (i.e. not blinded according to the clinical study protocol).
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inhospital efficacy and safety of pre-treatment with Thienopyridines. Survival up to one year after Diagnosis. Analysis and comparision of transport times between sites and countries accross Europe. | — |
Countries
Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain
Contacts
Public ContactSabine Köhler
Daiichi Sankyo Europe GmbH
Outcome results
None listed